Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

SDĚLENÍ

Ministerstva xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx a xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo xxxxxxxxxxxx xxxx sděluje, xx xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx nového xxxxx Xxxxxxx I - Xxxxxx zakázaných látek x xxxxx xxxxxxx xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve sportu.

S xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx České xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx listinu o xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx I xxxxxxxxx v platnost x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx dne 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx vstoupilo x xxxxxxxx dne 18. xxxxxx 2024 x xxxxxxxxx Přílohu X xxx xxx 2023, xxxxxxx od 1. ledna 2023, xxxxx xxxxxxxxx v xxxxxxxx xxx Xxxxxx xxxxxxxxx dne 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X xxx xxx 2024 x její xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. JUDr. Xxxxxx, Ph.D., XX.X., x. x.

xxxxxx xxxxxxx xxxxx právní x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Xxxxxxx xxxxxxxxxxx smlouvy do xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx antidopingového xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx rozsáhlém xxxxxxxxxxxx procesu xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx od 1. xxxxx 2024.

Oficiální xxxx Xxxxxxx zakázaných xxxxx x metod xxxx xxxxxxxxx WADA a xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx mezi xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx znění x xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxx x tomto Seznamu xxxxxxxxxx látek x xxxxx.

Xxxxxxxx Při xxxxxxx

Xxxxx XXXX xxx xxxx xxxxx neschválila xxxx xxxxxx, xx xxxxxx Xxx soutěži x xxxxxx xxxxxxx xxxxxxxxxxx xxxxx před půlnocí (xx 23:59 hodin) x den předcházející Xxxxxxx, xxxxx se xx Xxxxxxxxx zúčastnit, xx xx xxxxx Xxxxxxx x xxxxxxx xxxxxx Vzorku.

Zakázané stále

To xxxxxxx, xx xxxx xxxxx nebo xxxxxx xx xxxxxxxx Při xxxxxxx x Xxxx xxxxxx, xxx xx xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx článku 4.2.2 Světového xxxxxxxxxxxxxxx Xxxxxx „xxx účely xxxxxxxx článku 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx xxxx xxxxxxxxxx x Seznamu xxxxxxxxxx látek x xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx x článku „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx xxxxxxx x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx způsobem považovány xx méně xxxxxxxx xxxx xxxx xxxxxxxxxx xxx xxxx dopingové xxxxx nebo xxxxxx. Xxx xxxxx x xxxxx x xxxxxx, xxxxx Xxxxxxxxx pravděpodobně xxxx xxxx xxxxxx x xxxxxx xxxxx xxx ke xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Kodexu xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx jsou xxxx xxxxxx xxxxxxxx z xxxxxx jejich xxxxxxx xxxxxxxxxx ve xxxxxxxxxxx xxxx xxxxx xxxxxx. Xxxx Návykové xxxxx xxxx označovány xxxx xxxxx: kokain, diamorfin (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (THC).

S0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Specifické xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, na xxxxxx xx xxxxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxx Seznamu a xxxxx není v xxxxxxxx době schválena xxxxxx xxxxxxx zdravotnickým xxxxxxxxxx orgánem xxx xxxxxxx xxxxxxx u xxxx (xxxx. léčiva x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxx byl xxxxxxx, syntetické xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx zakázána xxxxx.

Xxxx xxxxx zahrnuje xxxxx xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) a xxxxxxxxxx xxxxxxxxx (xxxx. Reldesemtiv x Tirasemtiv).

S1 XXXXXXXXXX XXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Nespecifické xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)

Xxx xxxxxxxxx xxxxxx, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on)
•	7-keto-DHEA		•	metylklostebol
•	11ß-metyl-19-nortestosteron		•	metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on)
•	Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol)		•	norboleton
•	androstenedion (androst-4-en-3,17-dion)		•	norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- ol)		•	quinbolon
•	dimetandrolon (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)		&xxxx;•	xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT)

a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. andarin, enobosarm (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, S-23 a XX-11], xxxxxxx x xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X MIMETIKA

ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx látky x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky jsou xxxxxxxx.

X2.1. ERYTROPOETINY (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. darbepoetiny (xXXX); xxxxxxxxxxxxx (EPO); sloučeniny xxxxxxxx na EPO, [xxxx. EPO-Fc, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx hypoxii vyvolávajícího xxxxxxx (HIF), xxxx. xxxxxx; xxxxxxxxxxx (GSK1278863); XXX2; xxxxxxxxxx (BAY 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, např. X-11706.

X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx růstového xxxxxxx xxxx (XXX-β), např. xxxxxxxxxxxx; sotatercept.

S2.1.5 Agonisté xxxxxxxxx opravného receptoru, xxxx. xxxxxx XXX; xxxxxxxxxxxxx XXX (CEPO).

S2.2. XXXXXXXXX HORMONY X XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx stimulující xxxxxxxxxxx x mužů, mimo xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (XX),

• luteinizační xxxxxx (XX),

• hormon xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) x jeho xxxxxxxxxxx analogy (např. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, nafarelin x triptorelin),

 • kisspeptin x jeho xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx a xxxxxx uvolňující xxxxxxx, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.

X2.2.3 Růstový hormon (XX), xxxx xxxxxxx x xxxxxxxxx, xxxx xxxx xxxxxx:

• xxxxxxx xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. AOD-9604 x hGH 176–191.

X2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, mimo xxxx xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x xxxx analogy, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx x tesamorelin,

• xxxxxxxxxxx růstového xxxxxxx (XXX) x xxxxxx xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (MK-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x tabimorelin],

• xxxxxxx xxxxxxxxxx GH (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), XXXX-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, GHRP-5 a XXXX-6].

X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx xxxxxxx faktory (XXX)

• hepatocytový xxxxxxx xxxxxx (HGF)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x xxxx xxxxxxx

• xxxxxxxxxx růstové faktory (XXX)

• růstový xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX)

• xxxxxxxx-β4 x jeho xxxxxxxx, xxxx. XX-500

• vaskulárně-endoteliární xxxxxxx xxxxxx (VEGF)

a xxxxx xxxxxxx faktory xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx syntézu/degradaci xxxxxxxx ve svalech, xxxxxxxx nebo vazech, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě jsou Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx všech xxxxxxxxx izomerů xxxx xxxxxxxx.

Xxxx xxxx včetně:

•	arformoterol		•	indakaterol		•	reproterol		•	tretoquinol (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 mikrogramů xx 24 hodin x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;

• xxxxxxxxx formoterol: maximálně xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin;

• xxxxxxxxx vilanterol: maximálně 25 xxxxxxxxxx xx 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxx vyšším xxx 1000 xx/xx nebo xxxxxxxxxxx v xxxxxxxx xxxxxx než 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx x xxxx považována xx Xxxxxxxxx xxxxxxxxxxx nález (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že abnormální xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (xxxxxxxxx) xx xx výše xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX I XXXX XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx X4.1 a X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx do xxxx S4.3 a X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx modulátory jsou xxxxxxxx.

X4.1. XXXXXXXXXX AROMATÁZ

Mimo xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-ol)		•	androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (arimistan)
•	3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. ANTIESTROGENNÍ XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]

Xxxx xxxx včetně:

•	arformoterol		•	indakaterol		•	reproterol		•	tretoquinol (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX AKTIVINU XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx A		•	inhibitory xxxxxxxxxx, např.:
•	konkurenty xxxxxxxxx xxxxxxxx IIB, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx
	- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. ACE-031)			- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, propeptid myostatinu)
•	protilátky xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. bimagrumab)			- xxxxxxxxxx xxxxxxxxxxxxxx myostatin xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 aktivátory AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx receptoru xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) kyselina xxxxxx (GW1516, GW501516) x xxxxxxxx Xxx-xxxɑ , xxxx. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX LÁTKY

ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx v xxxx xxxxx jsou Specifické xxxxx.

Xxxxxxx diuretika a xxxxxxxxx látky, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. d- a x-, xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx xxxx.:

xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx xxxxxxxxxx; furosemid; xxxxxxxxx; xxxxxxxxx; spironolakton; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:

xxxxxxx, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x lokální oftalmologické xxxxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, brinzolamid);

• xxxxxxx xxxxxx felypresinu x zubní xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx a pseudoefedrinu xx Xxxxxx Sportovce xxxxxxxx xxxx případně Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx lokálního xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx nebo lokálního xxxxxx xxxxxxxxxxx x xxxxxxxx anestezii), bude xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx tuto xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx nebo xxxxx xxxxxxxxx látku.

ZAKÁZANÉ XXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx x xxxx třídě xxxx Xxxxxxxxxxxx x xxxxxxxx xxxxx x M2.2, xxx jsou Xxxxxxxxxx xxxxxx.

X1. MANIPULACE S XXXX A KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx je následující:

M1.1. Xxxxxx nebo xxxxxxxx xxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, allogenní (xxxxxxxxx) xxxx heterologní xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx xxxxxx Sportovci xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x xxxxxxxxxxxxx odběrovém xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (RSR13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx produkty, xxxx. xxxxxx xxxxxxxx xx xxxx hemoglobinu x xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx inhalací.

M1.3. Xxxxxxxxx xxxxx intravaskulární xxxxxxxxxx x xxxx xxxx x xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. CHEMICKÁ X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Podvádění xxxx Xxxxx x xxxxxx xx účelem porušit xxxxxxxxx a platnost Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, např. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více xxx xxxxxx 100 ml xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx ošetření, xxxxxxxxxxxxx xxxxxxx nebo klinických xxxxxxxxxxxxxx xxxxxxxxx.

X3. GENOVÝ X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx výkonu je xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx sekvence xxxxxx x/xxxx exprese xxxx xxxxxxxxxx xxxxxxxxxxx. Xx mimo jiné xxxxxxxx technologie xxxxx xxxx, umlčování xxxx x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x této třídě xxxx Specifické xxxxx x výjimkou xxxxx xxxxxxxxx x X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: kokain x metylendioxymetamfetamin (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

X6.X: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-fenylpiracetam (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx uveden v xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx a xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-dimetylpentylamin, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx x xxxx xxxxxxx, xxxx. xxxxxxxx, metedron a ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (metylendioxyamfetamin)
•	etylamfetamin		•	norfenefrin		•	tuaminoheptan
•	etilefrin		•	oktodrin (1,5-xxxxxxxxxxxxxxxx)

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx nebo xxxxxx použití (např. xxxxxxxxxx, xxxxxxxxxx, fenoxazolin, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, tramazolin, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Monitorovacího xxxxxxxx 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx zakázané xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, včetně xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 KANABINOIDY

ZAKÁZANÉ XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx přírodní x xxxxxxxxxx xxxxxxxxxxx xxxx zakázané, např.

• x xxxxxx (hašiš, xxxxxxxxx) a xxxxxxxxx xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx xxxxxxxxxxx napodobující xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx látky.

Všechny glukokortikoidy xxxx xxxxxxxx, pokud xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, perorální [včetně xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] nebo xxxxxxxx xxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx acetonid
•	kortizon		•	hydrokortizon
•	deflazakort		•	metylprednisolon

POZNÁMKA

• Jiné xxxxxxx xxxxxx (včetně xxxxxxxxxxx a xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, intranazálního, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx xx xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx x kde xx to xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• lukostřelba (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx na xxxxxx, akrobatické xxxxx / X-xxxxx x xxxxxxxxx U-rampa / xxx xxx

• xxxxxxxxxxxx xxxxx (XXX)

• podvodní xxxxxx (CMAS)* x xxxxxxxxxxxx xxxxxxx potápění, xxxx harpunou x xxxxxxx xx xxxx

• xxxxxxxx (všechny xxxxxxxxxx) (XXXX)

• xxxxx (XXX)

• xxxx (XXX)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx soutěž

Mimo xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;

¹⁾ katin (x-xxxxxxxxxxxxxxxx) x jeho x-xxxxxx: je xxxxxxxx xxxxx při xxxxxxxxxxx x xxxx xxxxx xxx 5 mikrogramů x 1 ml.

²⁾ xxxxxxxxxxxxx: xxxxxxxx pouze xxx xxxxxxxxxxx x xxxx xxxxx xxx 150 xxxxxxxxxx v 1 xx.

³⁾ efedrin x xxxxxxxxxxxx: zakázány xxx xxxxxxxxxxx v xxxx vyšší než 10 xxxxxxxxxx x 1 xx.

⁴⁾ xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, kofein, xxxxxxx, pipradrol a xxxxxxxx: xxxx látky xxxx xxxxxxxx do Xxxxxxxxxxxxxx programu 2024 x nejsou xxxxxxxxxx xx Zakázané xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx č. 19/2025 Xx. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud se xxxx xxxxxx derogační xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx